Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0032—Methine dyes, e.g. cyanine dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
  • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0056—Peptides, proteins, polyamino acids
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
  • C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines

Definitions

• This invention relates generally to novel cyanine and indocyanine dyes for use in imaging, diagnosis and therapy. Particularly, this invention relates to compositions of cyanine and indocyanine dyes wherein novel carbocyclic and heterocyclic moieties are incorporated into the polyene portion of the dye molecules.
• cyanine dye derivatives A major drawback in the use of cyanine dye derivatives is the potential for hepatobilliary toxicity resulting from the rapid clearance of these dyes by the liver (G. R. Cherrick, S. W. Stein, C. M. Leevy, et al., Indocyanine green: Observations on its physical properties, plasma decay, and hepatic extraction. J. Clinical Investigation, 1960, 39, 592-600). This is associated with the tendency of cyanine dyes to form aggregates in solution which could be taken up by Kupffer cells in the liver. Various attempts to obviate this problem have not been very successful.
• hydrophilic peptides typically, hydrophilic peptides, polyethyleneglycol or oligosaccharide conjugates have been used but these resulted in long-circulating products which are eventually cleared by the liver.
• Another major difficulty with current cyanine and indocyanine dye systems is that they offer a limited scope in the ability to induce large changes in the absorption and emission properties of these dyes. Attempts have been made to incorporate various heteroatoms and cyclic moieties into the polyene chain of these dyes (L. Strekowski, M. Lipowska, and G. Patonay, Substitution reactions of a nucleofugal group in hetamethine cyanine dyes. J. Org. Chem., 1992, 57, 4578- 4580; N.
• Tricyclic functional dyes for contrast enhancement in optical imaging US 5, 709, 845) but the resulting dye systems do not show large differences in absorption and emission maxima, especially beyond 830 nm where photacoustic diagnostic applications are very sensitive. They also possess prominent hydrophobic core which enhances liver uptake. Further, most cyanine dyes do not have the capacity to form dendrimers which are useful in biomedical applications.
• the present invention relates particularly to the novel composition comprising cyanine dyes of general formula 1
• W 1 and X 1 may be the same or different and are selected from the group consisting of -CR 0 R 11 , -0-, -NR 12 , -S-, and -Se;
• Q 1 is a single bond or is selected from the group consisting of -0-, -S-, -Se-, and -NR 13 ;
• Y 1 and Z 1 may be the same or different and are selected from the group consisting of - (CH 2 ) c -C0 2 H, -CH 2 -(CH 2 -0-CH 2 ) d -CH 2 -C0 2 H, -(CH 2 ) e -NH 2 , -CH 2 -(CH 2 -O-CH 2 )rCH 2 - NH 2 , -(CH 2 ) g -N(R 14 )-(CH 2 ) h -C0 2 H, and -(CH 2 )
• Formula 2 wherein a 2 and b 2 are defined in the same manner as a., and b.,; W 2 and X 2 are defined in the same manner W 1 and X 1 ; Q 2 is defined in the same manner as Q 1 ; R 16 and R 10 to R 15 are defined in the same manner as R 1 and R 10 to R 15 ; Y 2 is defined in the same manner as Y 1 ; Z 2 is defined in the same manner as Z 1 ; and R 17 to R 28 are defined in the same manner as R 2 to R 9 .
• the present invention also relates to the novel composition comprising cyanine dyes of general formula 3
• a ⁇ is a single or a double bond; if A ! is a single
• B 1 and C 1 may the same or different and are selected from the group consisting of -0-, -S-, -Se-, -P-, and -NR 38 and D 1 is selected from the group
• B 1 is selected from the
• R 29 to R 37 are selected from the group consisting of hydrogen, C1-C10 alkyl,
• R 38 to R 42 may be same or different and
• heterocyclic ring optionally containing one or more oxygen, nitrogen, or a sulfur atom.
• the present invention also relates to the novel composition
• the novel composition comprising
• W 4 and X 4 are defined in the same manner as W 1 and X 1 ;
• Y 4 is defined in the same manner as Y 1 ;
• Z 4 is defined in the same manner as Z 1 ;
• a 2 is
• a ⁇ B 2 , C 2 , and D 2 are defined in the same manner as A ⁇ B 2 , C 2 , and D 2 are defined in the same manner
• the present invention also relates to the novel composition comprising cyanine dyes of general formula 5
• Formula 5 wherein a 5 is defined in the same manner as a.,; W 5 and X 5 are defined in the same manner W 1 and X 1 ; Y 5 is defined in the same manner as Y 1 ; Z 5 is defined in the same manner as Z 1 ; A 3 is defined in the same manner as A.,; B 3 , C 3 , and D 3 are defined in the same manner as B.,, C,, and D.,; and R 58 to R 66 are defined in the same manner as R 29 to R 37 .
• the present invention also relates to the novel composition comprising cyanine dyes of general formula 6
• Formula 6 wherein a 6 is defined in the same manner as a.,; W 6 and X 6 are defined in the same manner as W 1 and X 1 ; Y 6 is defined in the same manner as Y 1 ; Z 6 is defined in the same manner as Z 1 ; A 4 is defined in the same manner as A.,; B 4 , C 4 , and D 4 are defined in the same manner as B 1t C,, and D.,; and R 67 to R 79 are defined in the same manner as R 29 to R 37 .
• This invention is also related to the method of conjugating the dyes of this invention to peptides or biomolecules by solid phase synthesis.
• This invention is also related to the method of preventing fluorescence quenching. It is known that cyanine dyes generally form aggregates in aqueous media leading to fluorescence quenching. We observed that in instances where the presence of hydrophobic core in the dyes lead fluorescence quenching, the addition of a biocompatible organic solvent such as 1-50% dimethylsulfoxide (DMSO) restored the fluorescence by preventing aggregation and allowed in vivo organ visualization.
• DMSO dimethylsulfoxide
• novel compositions of the present invention comprising dyes of formulas 1 to 6 offer significant advantages over those currently described in the art. As illustrated in Schemes 1-6, these dyes are designed to prevent aggregation in solution by preventing intramolecular and intermolecular ordered hydrophobic interactions. They also have multiple attachment sites proximal to the dye chromophore for ease of forming dendrimers. The presence of rigid and extended chromophore backbone enhances fluorescence quantum yield and extends the maximum absorption beyond 800 nm. Conjugation of biomolecules to these dyes are readily achievable.
• biomedical applications including, but not limited to, tomographic imaging of organs; monitoring of organ functions; coronary angiography; fluorescence endoscopy; detection, imaging, and therapy of tumors; laser guided surgery, photoacoustic and sonofluorescence methods; and the like. Specific embodiments to accomplish some of the aforementioned biomedical applications are given below.
• the dyes of the invention are useful for optical tomographic, endoscopic, photoacoustic and sonofluoresence applications for the detection and treatment of tumors and other abnormalities.
• the dyes of the invention are useful for localized therapy.
• the dyes of the invention are useful for the detection of the presence of tumors and other abnormalities by monitoring the blood clearance profile of the dyes.
• the dyes are useful for laser assisted guided surgery for the detection of micrometastases of tumors upon laparoscopy.
• the dye bioconjugates of the dyes of this invention are useful diagnosis of atherosclerotic plaques and blood clots.
• the novel dyes of the present invention are prepared according the methods well known in the art and are shown in Schemes 1-5 and their use in the synthesis of bioconjugates is shown in Scheme 6.
• R CONH peptide
• R' R (Bis conjugate) or COOH (Mono conjugate)
• the dyes according to the present invention have the general Formula 1 wherein a ⁇ and b 1 vary from 0 to 3; Q 1 is a single bond; R 1 to R 9 are hydrogens; W 1 and X 1 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , C((CH 2 OH)CH 3 , C((CH 2 ) zz OH) 2 ,
• Y 1 and Z 1 may be the same or different and are selected from the group consisting of -(CH 2 ) c -C0 2 H, -CH 2 -(CH 2 -0- CH 2 ) d -CH 2 -C0 2 H, -(CH 2 ) g -N(R 14 )-(CH 2 ) h -C0 2 H, and -(CH 2 ) r N(R 10 )-CH 2 -(CH 2 -0-CH 2 ) r CH 2 -C0 2 H; R
• the dyes according to the present invention have the general Formula 2 wherein a 2 and b 2 vary from 0 to 3; Q 2 is a single bond; R 16 to R 28 are hydrogens; W 2 and X 2 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , C((CH 2 OH)CH 3 , C((CH 2 ) zz OH) 2 , C((CH 2 ) zz C0 2 H)CH 3 , C((CH 2 ) z2 CO 2 H) 2 , C((CH 2 NH 2 )CH 3 , C((CH 2 NH 2 ) 2 , C((CH 2 ) Z2 NR pp R pz )CH 3 and C((CH 2 ) zz NR pp R pz ) 2 ; Y 2 and Z 2 may be the same or different and are selected from the group consisting of -(CH 2 ) c -CO 2 H, -CH
• the dyes according to the present invention have the general Formula 3 wherein a 3 and b 3 vary from 0 to 3;
• A. is a single bond;
• B 1 is selected from the group consisting of -0-, -S-, and -NR 38 ;
• D 1 is selected from the group consisting of -0-, -S-, and -NR 38 ;
• R 29 is a hydrogen, a halogen atom, a saccharide or a hydrophilic peptide;
• R 30 to R 37 are hydrogens;
• R 38 is selected from the group consisting of -hydrogen, C1-C10 alkyl, C1-C10 aryl, C1- C10 alkoxyl, C1-C10 polyalkoxyalkyl, -CH 2 (CH 2 -0-CH 2 ) c -CH 2 -OH, C1-C20 polyhydroxyalkyl, C1-C10 polyhydroxy
• C1-C10 polyalkoxyalkyl, -CH 2 (CH 2 -O-CH 2 ) 0 -CH 2 -OH, C1-C20 polyhydroxyalkyl, C1-
• R 67 is a hydrogen, a halogen atom, a saccharide
• R 68 to R 79 are hydrogens; W 6 and X 6 may be the same of
• R pp and R pz are the same or different and are selected from the group consisting of -(CH 2 ) c -C0 2 H, -CH 2 -(CH 2 -O-CH 2 ) d -CH 2 -C0 2 H, -(CH 2 ) g -N(R 14 )- (CH 2 ) h -C0 2 H and -(CH 2 ) r N(R 15 )-CH 2 -(CH 2 -0-CH 2 ) r CH 2 -CO 2 H; R 14 and R 15 may be
• compositions of the invention can be formulated into diagnostic compositions
• compositions for enteral or parenteral administration.
• compositions contain an effective amount of the dye along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
• parenteral for enteral or parenteral administration.
• Parenteral compositions may be injected directly or mixed with a large volume parenteral composition for systemic administration.
• Such solutions also may contain pharmaceutically acceptable buffers and, optionally, electrolytes such as sodium chloride.
• Formulations for enteral administration may vary widely, as is well known in the art.
• such formulations are liquids which include an effective amount of the dye in aqueous solution or suspension.
• Such enteral compositions may optionally include buffers, surfactants, thixotropic agents, and the like.
• Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
• the diagnostic compositions are administered in doses effective to achieve the desired enhancement. Such doses may vary widely; depending upon the particular dye employed, the organs or tissues which are the subject of the imaging procedure, the imaging equipment being used, and the like.
• compositions of the invention are used in the conventional manner.
• the compositions may be administered to a patient, typically a warmblooded animal, either systemically or locally to the organ or tissue to be imaged, and the patient then subjected to the imaging procedure.
• a combination of the above represents an important approach to the synthesis and use of novel cyanine and indocyanine dyes with a variety of photophysical and chemical properties.
• the dyes of this invention are new and they are useful for biomedical applications.
• the present invention is further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the scope of the invention in any manner. Reliable computational methods for the prediction of the absorption maxima of some of the dyes were also established. Standard techniques well known in the art or the techniques specifically described below are utilized.
• This compound was prepared as described in Example 1 except that 1 ,1 ,2- trimethylindole was used as the starting material.
• bromohexaoxyethyleneglycolpropiolic acid was used in place of bromopropanoic acid and the reaction was carried out in 1 ,2-dimethoxypropane.
• the reaction mixture was partitioned between 100 ml of methylene chloride and 100 ml of saturated sodium bicarbonate solution. The layers were separated and the methylene chloride layer was again washed with 100 ml of saturated sodium bicarbonate solution. The combined aqueous layers were extracted twice with 25 ml of methylene chloride. The combined methylene chloride layers were washed with 100 ml of brine, and dried over magnesium sulfate. The methylene chloride was removed with aspirator vacuum at ca. 35°C, and the remaining dimethylformamide was removed with vacuum at about 45°C. The crude material was left on a vacuum line over night at room temperature.
• the ether solution was decanted and the oil was again triturated with a 100 ml portion of ether.
• the ether was decanted and the combined ether solutions allowed to stand for about 2 hours to allow the triphenylphosphine oxide to crystallize.
• the ether solution was decanted from the crystals and the solid washed with 100 ml of ether.
• the volume of the combined ether abstracts was reduced with vacuum until a volume of about 25 ml was obtained. This was allowed to stand over night at 0°C.
• Ether (10 ml) was added to the cold mixture which was mixed to suspend the solid. The mixture was percolated through a column of 45 g of silica gel and eluted with ether, 75 ml fractions were collected.
• the hydroxy-indole compound is readily prepared by literature method (P. L. Southwick, J. G. Cairns, L. A. Ernst, and A. S. Waggoner, One pot Fischer synthesis of (2,3,3-trimethyl-3-H-indol-5-yl)-acetic acid derivatives as intermediates for fluorescent biolabels. Org. Prep. Proced. Int. Briefs, 1988, 20(3), 279-284).
• the intermediate 2-chloro-1-formyl-3-hydroxymethylenecyclohexane was prepared as described in the literature (G. A. Reynolds and K. H. Drexhage, Stable heptamethine pyrylium dyes that absorb in the infrared. J. Org. Chem., 1977, 42(5), 885-888).
• Equal volumes (40 mL each) of dimethylformamide (DMF) and dichloromethane were mixed and the solution was cooled to -10 °C in acetone-dry ice bath. Under argon atmosphere, phosphorus oxychloride (40 mL) in dichloromethane was added dropwise to the cool DMF solution.
• the octapeptide was prepared by an automated fluorenylmethoxycarbonyl
• Subsequent cartridges contained Fmoc-protected amino acids with side chain protecting groups for the following amino acids: Cys(Acm), Thr(t-Bu), Lys(Boc), Trp(Boc) and Tyr(t-Bu).
• the amino acid cartridges were placed on the peptide synthesizer and the product was synthesized from the C- to the N-terminal position.
• the peptide was precipitated with t-butyl methyl ether and lyophilized with wate ⁇ acetonitrile (2:3) mixture.
• the peptide was purified by HPLC and analyzed with LC/MS.
• the amino acid sequence of Octreotate is: D-Phe-Cys'-Tyr-D-Trp-Lys- Thr-Cys'-Thr, wherein Cys' indicates the presence of an intramolecular disulfide bond between two cysteine amino acids.
• Octreotide was prepared by the same procedure : D-Phe-Cys'-Tyr-D-Trp-Lys-Thr- Cys'-Thr-OH, wherein Cys' indicates the presence of an intramolecular disulfide bond between two cysteine amino acids.
• Bombesin analogs were prepared by the same procedure except that cyclization with thalium trifluoroacetate was not needed. Side-chain deprotection and cleavage
• Cholecystokinin octapeptide analogs were prepared as described for Octreotate without the cyclization step. Three analogs were prepared: Asp-Tyr-Met-Gly-Trp- Met-Asp-Phe-NH 2 ; Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH 2 ; D-Asp-Tyr-Nle-Gly-Trp- Nle-Asp-Phe-NH 2 ; Neurotensin analog was prepared as described for Octreotate without the cyclization step: D-Lys-Pro-Arg-Arg-Pro-Tyr-lle-Leu.
• the Octreotate was prepared as described in Example 6 but the peptide was not cleaved from the solid support and the N-terminal Fmoc group of Phe was retained. The thiol group was cyclized with thallium trifluoroacetate and the Phe was deprotected to liberate the free amine. Bisethylcarboxymethylindocyanine dye (53 mg, 75 ⁇ moles) was added to an activation reagent consisting of a 0.2 M solution of HBTU/HOBt in DMSO (375 ⁇ L), and 0.2 M solution of diisopropylethylamine in DMSO (375 ⁇ L).
• the activation was complete in about 30 minutes and the resin- bqund peptide (25 ⁇ moles) was added to the dye.
• the coupling reaction was carried out at room temperature for 3 hours.
• the mixture was filtered and the solid residue was washed with DMF, acetonitrile and THF.
• the peptide was cleaved from the resin and the side chain protecting groups were removed with a mixture of 85% trifluoroacetic acid, 2.5% water, 2.5% thioanisole and 2.5% phenol.
• the resin was filtered and cold t-butyl methyl ether (MTBE) was used to precipitate the dye-peptide conjugate which was dissolved in acetonitrile:water (2:3) mixture and lyophilized.
• MTBE cold t-butyl methyl ether
• the product was purified by HPLC to give the monoOctreotate- Bisethylcarboxymethylindocyanine dye (Cytate 1, 80%) and the bisOctreotate- Bisethylcarboxymethylindocyanine dye (Cytate 2, 20%).
• the monoOctreotate conjugate can be obtained almost exclusively (>95%) over the bis conjugate by reducing the reaction time to 2 hours. However, this also leads to incomplete reaction and the free Octreotate must be carefully separated from the dye conjugate in order to avoid saturation of the receptors by the non-dye conjugated peptide.
• Octreotate-bispentylcarboxymethylindocyanine dye was prepared as described above with some modifications.
• Bispentylcarboxymethylindocyanine dye (60 mg, 75 ⁇ moles) was added to an activation reagent consisting of a 0.2 M solution of HBTU/HOBt in DMSO (400 ⁇ L), and 0.2 M solution of diisopropylethylamine in DMSO (400 ⁇ L).
• the activation was complete in about 30 minutes and the resin- bound peptide (25 ⁇ moles) was added to the dye.
• the reaction was carried out at room temperature for 3 hours.
• the mixture was filtered and the solid residue was washed with DMF, acetonitrile and THF.
• the peptide was cleaved from the resin and the side chain protecting groups were removed with a mixture of 85% trifluoroacetic acid, 2.5% water, 2.5% thioanisole and 2.5% phenol.
• the resin was filtered and cold t-butyl methyl ether (MTBE) was used to precipitate the dye-peptide conjugate which was dissolved in acetonitrile:water (2:3) mixture and lyophilized.
• MTBE cold t-butyl methyl ether

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Oncology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Saccharide Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Indole Compounds (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23923665

Family Applications (1)

Country Status (5)

Cited By (6)

Families Citing this family (32)

Citations (2)

Family Cites Families (19)

• 2000
  • 2000-01-18 US US09/484,322 patent/US6395257B1/en not_active Expired - Lifetime
• 2001
  • 2001-01-17 AU AU2001229513A patent/AU2001229513A1/en not_active Abandoned
  • 2001-01-17 EP EP01942624A patent/EP1250333A4/en not_active Withdrawn
  • 2001-01-17 JP JP2001553766A patent/JP2003520868A/ja not_active Withdrawn
  • 2001-01-17 WO PCT/US2001/001407 patent/WO2001053292A1/en not_active Ceased
  • 2001-05-23 US US09/864,011 patent/US6706254B2/en not_active Expired - Fee Related

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events